Literature DB >> 23609190

Upregulation of miR-2861 and miR-451 expression in papillary thyroid carcinoma with lymph node metastasis.

Zhihong Wang1, Hao Zhang, Ping Zhang, Jing Li, Zhongyan Shan, Weiping Teng.   

Abstract

MicroRNA (miRNA) expression is deregulated in many types of human cancers, including thyroid cancer. The purpose of this study was to investigate miRNA deregulation in papillary thyroid carcinoma (PTC), particularly with lymph node (LN) metastasis. To identify the miRNA signature in PTC with LN metastasis, miRNAs isolated from PTC patients with LN metastasis (n = 3) and without LN (NLN) metastasis (n = 3) were used for microarray analysis. Four differentially expressed miRNAs including miR-2861, miR-451, miR-193b, and miR-1202 were selected for further validation between the LN group (n = 51) and the NLN group (n = 36) using real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The miRNA microarray results showed that compared to the NLN group, upregulation of four miRNAs including miR-2861, miR-451, miR-193b, and miR-1202 was associated with LN metastasis, whereas four other miRNAs including miR-let-7i, miR-542-5p, miR-664*, and miR-564 were downregulated in the LN group. In the validation cohort, the expression of either miR-2861 or miR-451 in the LN group was significantly greater than that in the NLN group (P = 0.004 and 0.026, respectively). Furthermore, the expression levels of miR-2861 and miR-451 in lateral lymph node (LLN) metastasis were significantly greater than those in central lymph node (CLN) metastasis (P = 0.007 and 0.001, respectively). Upregulated expression of miR-2861 and miR-451 in PTC with LN metastasis represents a unique miRNA signature associated with the prognosis and progression of PTC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23609190     DOI: 10.1007/s12032-013-0577-9

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  21 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  MiRNA-451 plays a role as tumor suppressor in human glioma cells.

Authors:  Yang Nan; Lei Han; Anling Zhang; Guangxiu Wang; Zhifan Jia; Yang Yang; Xiao Yue; Peiyu Pu; Yue Zhong; Chunsheng Kang
Journal:  Brain Res       Date:  2010-09-18       Impact factor: 3.252

3.  Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection.

Authors:  Yasuhiro Ito; Takuya Higashiyama; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kanji Kuma; Akira Miyauchi
Journal:  World J Surg       Date:  2007-11       Impact factor: 3.352

4.  MicroRNA signature in thyroid fine needle aspiration cytology applied to "atypia of undetermined significance" cases.

Authors:  Rulong Shen; Sandya Liyanarachchi; Wei Li; Paul E Wakely; Motoyasu Saji; Jie Huang; Rebecca Nagy; Tisha Farrell; Matthew D Ringel; Albert de la Chapelle; Richard T Kloos; Huiling He
Journal:  Thyroid       Date:  2011-12-02       Impact factor: 6.568

5.  MicroRNAs as a potential prognostic factor in gastric cancer.

Authors:  Baruch Brenner; Moshe B Hoshen; Ofer Purim; Miriam Ben David; Karin Ashkenazi; Gideon Marshak; Yulia Kundel; Ronen Brenner; Sara Morgenstern; Marisa Halpern; Nitzan Rosenfeld; Ayelet Chajut; Yaron Niv; Michal Kushnir
Journal:  World J Gastroenterol       Date:  2011-09-21       Impact factor: 5.742

6.  Expression of microRNAs in basal cell carcinoma.

Authors:  M Sand; M Skrygan; D Sand; D Georgas; S A Hahn; T Gambichler; P Altmeyer; F G Bechara
Journal:  Br J Dermatol       Date:  2012-08-20       Impact factor: 9.302

Review 7.  BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

Authors:  Mingzhao Xing
Journal:  Endocr Rev       Date:  2007-10-16       Impact factor: 19.871

8.  Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma.

Authors:  Chen-Kai Chou; Kuender D Yang; Fong-Fu Chou; Chao-Cheng Huang; Yueh-Wen Lan; Ya-Fang Lee; Hong-Yo Kang; Rue-Tsuan Liu
Journal:  J Clin Endocrinol Metab       Date:  2012-12-21       Impact factor: 5.958

9.  Overexpression of miR-221 is associated with aggressive clinicopathologic characteristics and the BRAF mutation in papillary thyroid carcinomas.

Authors:  Yi-Li Zhou; Chao Liu; Xuan-xuan Dai; Xiao-Hua Zhang; Ou-Chen Wang
Journal:  Med Oncol       Date:  2012-08-02       Impact factor: 3.064

10.  A microRNA expression signature of human solid tumors defines cancer gene targets.

Authors:  Stefano Volinia; George A Calin; Chang-Gong Liu; Stefan Ambs; Amelia Cimmino; Fabio Petrocca; Rosa Visone; Marilena Iorio; Claudia Roldo; Manuela Ferracin; Robyn L Prueitt; Nozumu Yanaihara; Giovanni Lanza; Aldo Scarpa; Andrea Vecchione; Massimo Negrini; Curtis C Harris; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

View more
  31 in total

1.  The prognostic value of miRNA146a in follicular thyroid carcinoma.

Authors:  Luca Roncati; Manuela Simoni; Antonio Maiorana
Journal:  Med Oncol       Date:  2013-08-28       Impact factor: 3.064

Review 2.  MicroRNAs in the thyroid.

Authors:  Myriem Boufraqech; Joanna Klubo-Gwiezdzinska; Electron Kebebew
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2016-11-01       Impact factor: 4.690

3.  MicroRNA-215 is a potential prognostic marker for cervical cancer.

Authors:  Hua Liang; Yan Li; Ruo-Yu Luo; Fu-Jin Shen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-04-08

Review 4.  Noncoding RNAs in endocrine malignancy.

Authors:  Jessica Kentwell; Justin S Gundara; Stan B Sidhu
Journal:  Oncologist       Date:  2014-04-09

5.  Increased expression of SPRR1A is associated with a poor prognosis in pancreatic ductal adenocarcinoma.

Authors:  Kohei Yamakawa; Michiyo Koyanagi-Aoi; Keiichiro Uehara; Atsuhiro Masuda; Hiroaki Yanagimoto; Hirochika Toyama; Takumi Fukumoto; Yuzo Kodama; Takashi Aoi
Journal:  PLoS One       Date:  2022-05-26       Impact factor: 3.752

6.  Cancer stem cells as a potential therapeutic target in thyroid carcinoma.

Authors:  Luisa Vicari; Cristina Colarossi; Dario Giuffrida; Ruggero De Maria; Lorenzo Memeo
Journal:  Oncol Lett       Date:  2016-08-02       Impact factor: 2.967

7.  Downregulation of long noncoding RNA NONHSAT037832 in papillary thyroid carcinoma and its clinical significance.

Authors:  Xiabin Lan; Wei Sun; Ping Zhang; Liang He; Wenwu Dong; Zhihong Wang; Siming Liu; Hao Zhang
Journal:  Tumour Biol       Date:  2015-11-26

8.  Overexpression of miR-1260b in Non-small Cell Lung Cancer is Associated with Lymph Node Metastasis.

Authors:  Limin Xu; Liqin Li; Jing Li; Hongwei Li; Qibin Shen; Jinliang Ping; Zhihong Ma; Jing Zhong; Licheng Dai
Journal:  Aging Dis       Date:  2015-11-17       Impact factor: 6.745

9.  Up-regulation of microRNA-664 inhibits cell growth and increases cisplatin sensitivity in cervical cancer.

Authors:  Yao Yang; Hong Liu; Xi Wang; Long Chen
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 10.  The role of microRNAs in different types of thyroid carcinoma: a comprehensive analysis to find new miRNA supplementary therapies.

Authors:  S Pishkari; M Paryan; M Hashemi; E Baldini; S Mohammadi-Yeganeh
Journal:  J Endocrinol Invest       Date:  2017-07-31       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.